GUIDEWIRE MODEL UNKNOWN
Report
- Report Number
- 2029214-2015-00407
- Event Type
- Injury
- Date Received
- April 21, 2015
- Date of Event
- April 12, 2008
- Report Date
- March 25, 2015
- Manufacturer
- COVIDIEN (IRVINE)
- Product Code
- DQX
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- GR
- Reporter Occupation
- OTHER
Narratives
HTTP://WWW.NCBI.NLM.NIH.GOV/PUBMED/18408923.THIS REPORT WAS CREATED TO CAPTURE THE EVENTS RELATED TO THE UNKNOWN GUIDEWIRE. THE GUIDEWIRE WAS NOT RETURNED FOR ANALYSIS; THEREFORE, THE EVENT CAUSE COULD NOT BE DETERMINED. THE LOT HISTORY RECORD REVIEW WAS NOT POSSIBLE SINCE THE LOT NUMBER WAS NOT REPORTED. (B)(4).
CITATION: VASILIOS KATSARIDIS ET AL. CURATIVE EMBOLIZATION OF CEREBRAL ARTERIOVENOUS MALFORMATIONS (AVMS) WITH ONYX IN 101 PATIENTS. NEURORADIOLOGY (2008) 50:589¿597. DOI 10.1007/S00234-008-0382-X. THE FOLLOWING REPORT WAS RECEIVED BY MEDTRONIC THROUGH LITERATURE REVIEW: PATIENTS WHO WERE TREATED WITH ONYX EMBOLIZATION FOR A BRAIN ARTERIOVENOUS MALFORMATIONS (AVM) FROM 1 JANUARY 2004 TO 31 DECEMBER 2007 (4 YEARS). 101 PATIENTS WERE IDENTIFIED (43 WOMEN, 58 MEN; MEAN AGE 38.8 YEARS; AGE RANGE (14-65). ONE PATIENT (1/101, 0.5%) HAD A SEVERE INTRA-PARENCHYMAL HEMORRHAGE IN THE OCCIPITAL LOBE DUE TO THE PERFORATION OF A FEEDING ARTERY BY THE GUIDE-WIRE AND WAS TREATED BY SURGICAL REMOVAL OF BOTH THE HEMATOMA AND THE MALFORMATION; THIS PATIENT SUBSEQUENTLY HAD AN EXCELLENT RECOVERY. PROCEDURE WAS PERFORMED WITH A COMBINATION OF THE FLOW-GUIDED AND THE WIRE-GUIDED TECHNIQUES USING 0.010 INCH OR A 0.008 INCH WIRE (SILVERSPEED OR MIRAGE). IT IS UNKNOWN WHICH WAS USED IN THIS EVENT. INFORMATION RECEIVED FROM THE SAME ARTICLE AS MFR#S: 2029214-2015-00362, 2029214-2015-00363, 2029214-2015-00402, 2029214-2015-00408.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 264674 | GUIDEWIRE MODEL UNKNOWN | GUIDEWIRE, CATHETER | DQX | COVIDIEN (IRVINE) |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 39 YR | Other| R |